Table 1.
Table shows al drugs used, their mechanisms of action and their involvement in clinical trials against breast cancer or other tumors2,3.
| Drug | Synonym | Target | Trials | |
|---|---|---|---|---|
| BC | Others | |||
| AZD5363 | PKB/AKT isoforms inhibitor | ✓ | ✓ | |
| AZD7762 | ATP-competitive CHK1/2 inhibitor | ✓ | ||
| AZD8055 | ATP-competitive mTORC1/C2 inhibitor | ✓ | ||
| BYL719 | ALPELISIB | PI3K α-isoform (PIK3CA) specific inhibitor | ✓ | ✓ |
| ERLOTINIB | TARCEVA | Epidermal Growth Factor Receptor (EGFR) tyrosine kinases inhibitor | ✓ | ✓ |
| GEFITINIB | IRESSA | Epidermal Growth Factor Receptor (EGFR) tyrosine kinases inhibitor | ✓ | ✓ |
| GSK1070916 | ATP competitive inhibitor of Aurora B and C kinases | ✓ | ||
| GSK1120212 | TRAMETINIB | MEK 1/2 inhibitor | ✓ | ✓ |
| LEE011 | RIBOCICLIB | Cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor | ✓ | ✓ |
| SCH772984 | ATP competitive inhibitor of ERK1 and ERK2 | |||
| DOXORUBICIN | ADRIAMICIN | DNA intercalant, TOPOiso II inhibitor | ✓ | ✓ |
| DOCETAXEL | TAXOTERE | Binds tubulin inducing cell-cycle arrest at the G2/M phase. Vascular endothelial growth factor (VEGF) inhibitor | ✓ | ✓ |
| AMG511 | Selective pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor | |||
| XL765 | VOXATALISIB | Reversible ATP-competitive inhibitor of pan-Class I PI3K (α, β, γ, and δ) and mTORC1/mTORC2 | ✓ | ✓ |
All drugs were purchased from Chemietek.